Mesothelioma
Primary Outcome Measures Dose-limiting toxicity （DLT） [ Time Frame: After 28 days of single infusion ] Safety Secondary Outcome Measures Maximum tolerated dose (MTD) [ Time Frame: After 28 days of single infusion ] Tolerability Objective response rate (ORR) [ Time Frame: Month 12 ] Clinical response will be assessed by RECIST 1.1. Progression-free survival (PFS) [ Time Frame: Month 12 ] PFS of patients receiving αPD1-MSLN-CAR T cells Overall survival…
Genetically modified T cells are a promising treatment for those suffering from mesothelioma. There is only data from five patients, but the results so far look good. The Phase I part of the study is looking at the safety and efficacy of the treatment and is finding out what dosage is best for treating people.…
Primary Outcome Measures Feasibility and acceptability as measured by participant rates of enrollment [ Time Frame: 6 months ] Feasibility assessed by % of patients that agree to participate. Project feasible if >30% of the patients approached agree to participate Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0 [ Time Frame: Time of magnesium infusion till 2…
Peritoneal mesothelioma is a rare condition with only 400 cases diagnosed every year. Patients diagnosed with the cancer are not living as long as they could because of the underutilization of surgery. Surgery is only performed on a third of patients even though there are people that would benefit and qualify for it. When patients…
Primary Outcome Measures Prospectively gather information related to the use of high-resolution computed tomographic imaging (HRCT) including photon counting CT (PCCT) scans, together with minimally invasive surveillance for early detection of mesotheliomas in pts with … [ Time Frame: annual or bi-annual followup, 5 years interim analysis ] Documentation of the counts, incidence, and frequencies…
Primary Outcome Measures Non-progression proportion [ Time Frame: 6 month after starting talazoparib ] The non-progression proportion is defined as the proportion of patients free of progression 6 months after talazoparib start. Disease progression will be based on (i) tumor assessment made by the investigators according to the RECIST 1.1 criteria and/or, ii) non-equivocal…
Mesothelioma is a devastating cancer that primarily affects the lining of the lungs and abdomen. Once exposed to asbestos, it can take years to develop and after being diagnosed, there are not many options for patients. Since there is not a cure, clinical trials can give people hope and can potentially help extend their lives.…
Curcumin could soon be used to treat mesothelioma patients. It is a natural compound found in turmeric, a spice commonly found in Asian dishes. This natural compound has been used as an anti-inflammatory alongside other treatments, but it could soon be used as a standard mesothelioma treatment, which is what doctors in Philadelphia are hoping…
The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
This is a phase II, single arm, multicenter and open-label study to evaluate the efficacy, safety and pharmacokinetic of HMPL-453 in patient with advanced Malignant Mesothelioma
